PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33040459-7 2021 In Ba/F3 cells transformed by NPM-ALK and Ki-JK cells, p53 activation induced by knockdown of EBP2 was significantly inhibited by Akt inhibitor GDC-0068, mTORC1 inhibitor rapamycin, and knockdown of Raptor, an essential component of mTORC1. Sirolimus 171-180 tumor protein p53 Homo sapiens 55-58 33860865-5 2021 The study also reveals that treatment of TSC mutant cells with the drug candidate Proxison combined with reduced concentration of rapamycin can increase production of reactive oxygen species (ROS), can modify miRNA expression pattern associated with p53 regulation and can reduce cell viability. Sirolimus 130-139 tumor protein p53 Homo sapiens 250-253 33614662-0 2021 Rapamycin Protects Skin Fibroblasts From UVA-Induced Photoaging by Inhibition of p53 and Phosphorylated HSP27. Sirolimus 0-9 tumor protein p53 Homo sapiens 81-84 33614662-5 2021 In addition, treatment with rapamycin significantly increased cell autophagy levels, decreased the expression of p53 and phosphorylated HSP27, and reduced genotoxic and oxidative cellular stress levels in UVA-induced HDFs. Sirolimus 28-37 tumor protein p53 Homo sapiens 113-116 27825169-9 2016 Importantly, the rapamycin resistant cells demonstrated attenuated accumulation of p53 in the nucleus in response to rapamycin treatment. Sirolimus 17-26 tumor protein p53 Homo sapiens 83-86 29871517-16 2018 Treatment with rapamycin decreased p53 accumulation, and 3-MA inhibited the decrease in p53 induced by HPC. Sirolimus 15-24 tumor protein p53 Homo sapiens 35-38 27070592-5 2016 In addition, suppression of mTOR activity by rapamycin decreased the level of activity of p70S6K, induced upregulation of p53 and caspase 3, and led to increase of apoptosis in K562R(IMT) cells. Sirolimus 45-54 tumor protein p53 Homo sapiens 122-125 26937175-7 2016 Depletion of p53 or HIF1alpha impaired both antagonist-elicited apoptoses to differential extents, corresponding to their expression changes responding to chemical treatments, and double knockdown of p53 and HIF1alpha remarkably hindered MI-319- or rapamycin-induced apoptosis, suggesting that both p53 and HIF1alpha are involved in MDM2 or mTOR antagonist-induced apoptosis. Sirolimus 249-258 tumor protein p53 Homo sapiens 13-16 26937175-7 2016 Depletion of p53 or HIF1alpha impaired both antagonist-elicited apoptoses to differential extents, corresponding to their expression changes responding to chemical treatments, and double knockdown of p53 and HIF1alpha remarkably hindered MI-319- or rapamycin-induced apoptosis, suggesting that both p53 and HIF1alpha are involved in MDM2 or mTOR antagonist-induced apoptosis. Sirolimus 249-258 tumor protein p53 Homo sapiens 200-203 26937175-7 2016 Depletion of p53 or HIF1alpha impaired both antagonist-elicited apoptoses to differential extents, corresponding to their expression changes responding to chemical treatments, and double knockdown of p53 and HIF1alpha remarkably hindered MI-319- or rapamycin-induced apoptosis, suggesting that both p53 and HIF1alpha are involved in MDM2 or mTOR antagonist-induced apoptosis. Sirolimus 249-258 tumor protein p53 Homo sapiens 200-203 27616194-10 2016 Finally, we found that the extracellular signal-regulated kinase 1/2 (ERK1/2) signal was regulated by p53 whose expression was induced by rapamycin. Sirolimus 138-147 tumor protein p53 Homo sapiens 102-105 27616194-11 2016 Overall, this study demonstrates that rapamycin inhibited the proliferation of Huh7 cells by up-regulating the expression of p53 and down-regulating the ERK1/2 signal, indicating that p53 is a useful biomarker for anti-cancer therapy using the specific inhibitor of mTOR signal, rapamycin, against hepatocellular carcinoma cells. Sirolimus 38-47 tumor protein p53 Homo sapiens 125-128 27616194-11 2016 Overall, this study demonstrates that rapamycin inhibited the proliferation of Huh7 cells by up-regulating the expression of p53 and down-regulating the ERK1/2 signal, indicating that p53 is a useful biomarker for anti-cancer therapy using the specific inhibitor of mTOR signal, rapamycin, against hepatocellular carcinoma cells. Sirolimus 38-47 tumor protein p53 Homo sapiens 184-187 27616194-11 2016 Overall, this study demonstrates that rapamycin inhibited the proliferation of Huh7 cells by up-regulating the expression of p53 and down-regulating the ERK1/2 signal, indicating that p53 is a useful biomarker for anti-cancer therapy using the specific inhibitor of mTOR signal, rapamycin, against hepatocellular carcinoma cells. Sirolimus 279-288 tumor protein p53 Homo sapiens 184-187 27825169-10 2016 Moreover, the inhibition of MDM2 by siMDM2 sensitizes A498 cells to rapamycin through the activation of p53. Sirolimus 68-77 tumor protein p53 Homo sapiens 104-107 26471831-5 2016 RESULTS: mTOR inhibitors AZD8055, RAD-001, rapamycin and BEZ235 induced synergistic cytotoxicity with the Chk1 inhibitor V158411 in p53 mutant colon cancer cells. Sirolimus 43-52 tumor protein p53 Homo sapiens 132-135 24915467-1 2014 The activation of the p53 pathway by 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), a molecule that mimics metabolic stress, is attenuated by rapamycin, an inhibitor of mTOR kinase, immunosuppressant, and cancer drug. Sirolimus 150-159 tumor protein p53 Homo sapiens 22-25 24915467-0 2014 Rapamycin prevents strong phosphorylation of p53 on serine 46 and attenuates activation of the p53 pathway in A549 lung cancer cells exposed to actinomycin D. Sirolimus 0-9 tumor protein p53 Homo sapiens 45-48 24915467-5 2014 Rapamycin inhibited the accumulation of phospho-Ser46 p53, attenuated upregulation of some p53 target genes, and altered cell-cycle progression. Sirolimus 0-9 tumor protein p53 Homo sapiens 54-57 24915467-0 2014 Rapamycin prevents strong phosphorylation of p53 on serine 46 and attenuates activation of the p53 pathway in A549 lung cancer cells exposed to actinomycin D. Sirolimus 0-9 tumor protein p53 Homo sapiens 95-98 24915467-5 2014 Rapamycin inhibited the accumulation of phospho-Ser46 p53, attenuated upregulation of some p53 target genes, and altered cell-cycle progression. Sirolimus 0-9 tumor protein p53 Homo sapiens 91-94 21945951-8 2011 Furthermore, p53 activation by AICAR was blocked by rapamycin, a specific inhibitor of the mTOR kinase, which is a crucial regulator of cell growth. Sirolimus 52-61 tumor protein p53 Homo sapiens 13-16 25482947-6 2014 We found that inhibitors of the mTOR pathway including rapamycin, wortmannin, and caffeine blunted the p53 response to nucleolar stress induced by actinomycin D. Sirolimus 55-64 tumor protein p53 Homo sapiens 103-106 25482947-10 2014 We found that rapamycin mimicked the effect of RPL11 depletion in terms of blunting the p53 response to nucleolar stress. Sirolimus 14-23 tumor protein p53 Homo sapiens 88-91 22710790-0 2012 Rapamycin induces p53-independent apoptosis through the mitochondrial pathway in non-small cell lung cancer cells. Sirolimus 0-9 tumor protein p53 Homo sapiens 18-21 22710790-7 2012 We found that rapamycin induced apoptosis in NSCLC cell lines with p53 mutations. Sirolimus 14-23 tumor protein p53 Homo sapiens 79-82 22559167-7 2012 The effects of rapamycin and/or bortezomib on the mRNA expression levels of p53, p27, p21 and Bcl-2 family in HCCLM3 cells were evaluated by RT-PCR. Sirolimus 15-24 tumor protein p53 Homo sapiens 76-79 20811722-0 2010 Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status. Sirolimus 10-19 tumor protein p53 Homo sapiens 103-106 20457898-8 2010 Like rapamycin, which is known to suppress senescence, p53 inhibited the mTOR pathway. Sirolimus 5-14 tumor protein p53 Homo sapiens 55-58 20368736-6 2010 We also found that p53 knockdown or inhibition of mTOR activity by rapamycin cotreatment impairs 6-TG- and 5-FU-induced upregulation of BNIP3 protein levels and autophagy. Sirolimus 67-76 tumor protein p53 Homo sapiens 19-22 19337030-7 2009 Further autophagy induction with rapamycin protects DA neurons from lactacystin-mediated cell death by downregulating p53 and its related apoptotic pathways and by inducing autophagy to degrade aggregated proteins. Sirolimus 33-42 tumor protein p53 Homo sapiens 118-121 19815708-6 2009 Here, we show that sirolimus and paclitaxel differentially induce self-digesting autophagy in vascular endothelial cells with changes in expression of LC3B, p53, and Bcl-2, considerably suppressing re-endothelialization and revascularization. Sirolimus 19-28 tumor protein p53 Homo sapiens 157-160 15218033-1 2004 Under serum-free conditions, rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), induces a cellular stress response characterized by rapid and sustained activation of the apoptosis signal-regulating kinase 1 (ASK1) signaling pathway and selective apoptosis of cells lacking functional p53. Sirolimus 29-38 tumor protein p53 Homo sapiens 298-301 19261747-4 2009 Furthermore, the synergistic effects of p53 and Pten deletion are mediated by deregulation of mammalian target of rapamycin (mTOR) signaling, consistent with the ability of rapamycin to block bladder tumorigenesis in preclinical studies. Sirolimus 114-123 tumor protein p53 Homo sapiens 40-43 18758183-2 2009 P27 and P53 play important roles in the signal transduction leading to neointimal growth inhibition and induction of apoptosis of smooth muscle cells due to rapamycin and paclitaxel. Sirolimus 157-166 tumor protein p53 Homo sapiens 8-11 18838865-4 2008 Chemical inducers of autophagy (including rapamycin, lithium, tunicamycin and ABT737) induced rapid depletion of the p53 protein. Sirolimus 42-51 tumor protein p53 Homo sapiens 117-120 18604159-6 2008 Several distinct autophagy inducers (e.g., starvation, rapamycin, lithium, tunicamycin and thapsigargin) stimulate the rapid degradation of p53. Sirolimus 55-64 tumor protein p53 Homo sapiens 140-143 16651424-5 2006 In addition, we found that inhibition of p53 by NIC-1 mainly occurs through mammalian target of rapamycin (mTOR) using phosphatidylinositol 3-kinase (PI3K)-Akt/protein kinase B (PKB) pathway as the mTOR inhibitor, rapamycin treatment abrogated NIC-1 inhibition of p53 and reversed the chemoresistance. Sirolimus 96-105 tumor protein p53 Homo sapiens 41-44 16651424-5 2006 In addition, we found that inhibition of p53 by NIC-1 mainly occurs through mammalian target of rapamycin (mTOR) using phosphatidylinositol 3-kinase (PI3K)-Akt/protein kinase B (PKB) pathway as the mTOR inhibitor, rapamycin treatment abrogated NIC-1 inhibition of p53 and reversed the chemoresistance. Sirolimus 96-105 tumor protein p53 Homo sapiens 264-267 18818522-2 2008 Moreover, autophagy-inducing stimuli such as nutrient depletion, rapamycin or lithium cause the depletion of cytoplasmic p53, which in turn is required for the induction of autophagy. Sirolimus 65-74 tumor protein p53 Homo sapiens 121-124 12030785-6 2001 In addition, the status of ATM, p53, PTEN/Akt and 14-3-3 are also associated with rapamycin sensitivity. Sirolimus 82-91 tumor protein p53 Homo sapiens 32-35 12820963-1 2003 Under serum-free conditions, rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), induces apoptosis of cells lacking functional p53. Sirolimus 29-38 tumor protein p53 Homo sapiens 140-143 12543789-1 2003 The mTOR inhibitor rapamycin induces G1 cell cycle accumulation and p53-independent apoptosis of the human rhabdomyosarcoma cell line Rh1. Sirolimus 19-28 tumor protein p53 Homo sapiens 68-71 11309295-0 2001 p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. Sirolimus 37-46 tumor protein p53 Homo sapiens 0-3 11309295-6 2001 Infection of Rh30 cells with either Ad-p53 or Ad-p21, but not control virus (Ad-beta-gal), induced G(1) accumulation, up-regulation of p21(CIP1), and complete protection of cells from rapamycin-induced apoptosis. Sirolimus 184-193 tumor protein p53 Homo sapiens 39-42 11309295-13 2001 In contrast, rapamycin significantly induced apoptosis in cells deficient in p53 ( approximately 2.4-fold) or p21(CIP1) ( approximately 5.5-fold). Sirolimus 13-22 tumor protein p53 Homo sapiens 77-80 10753954-7 2000 Rapamycin blocked p70(S6k) phosphorylation induced by NO and also inhibited p53 phosphorylation and p21 expression whereas PD98059 only prevented the NO-induced increase in p21 protein without influencing either p53 activation or p21 mRNA expression. Sirolimus 0-9 tumor protein p53 Homo sapiens 76-79 11309295-20 2001 Taken together, the data suggest that p53 cooperates in enforcing G(1) cell cycle arrest, leading to a cytostatic response to rapamycin. Sirolimus 126-135 tumor protein p53 Homo sapiens 38-41 10753954-7 2000 Rapamycin blocked p70(S6k) phosphorylation induced by NO and also inhibited p53 phosphorylation and p21 expression whereas PD98059 only prevented the NO-induced increase in p21 protein without influencing either p53 activation or p21 mRNA expression. Sirolimus 0-9 tumor protein p53 Homo sapiens 212-215 10029080-0 1999 Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Sirolimus 0-9 tumor protein p53 Homo sapiens 66-69 21528311-0 1997 Rapamycin-induced apoptosis is p53-independent in human prostate carcinoma PC-3 cells. Sirolimus 0-9 tumor protein p53 Homo sapiens 31-34 35589683-3 2022 p53 inhibits the mammalian target of rapamycin complex 1 (mTORC1) signaling to attenuate the protein level of mitochondrial fission process 1 (MTFP1), which fosters the pro-fission dynamin-related protein 1 (Drp1) phosphorylation. Sirolimus 37-46 tumor protein p53 Homo sapiens 0-3 9865315-0 1998 In vitro transcription and translation of the tumour suppressor protein P53: qualitative and quantitative effects of FK506 and rapamycin. Sirolimus 127-136 tumor protein p53 Homo sapiens 72-75 34948101-7 2021 Moreover, a higher level of p53 protein in the presence of rapamycin or doxorubicin and the combination of both antibiotics was noticed in PCBP2-overexpressed cells compared to control cells. Sirolimus 59-68 tumor protein p53 Homo sapiens 28-31 35356282-14 2022 Pre-treatment with rapamycin or PFT-alpha significantly down-regulated the levels of SA beta-Gal, SAHF, p-p53, p21, autophagy related protein p62, the percentage of cells in the G0/G1 phase, and significantly up-regulated DeltaPsim, autophagy related protein BECN1, autophagosomes and autolysosomes compared with cells only treated with AOPPs. Sirolimus 19-28 tumor protein p53 Homo sapiens 106-109